Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) in recurrent/persistent ovary, fallopian tube, primary peritoneal, endometrial, or endometriosis-associated clear cell carcinoma characterized for the retention or loss of BAF250a Expression
IRB GOG0283
CC 14-851
Hospital Fairview, Hillcrest, Main Campus
Phase Phase 2
Disease Gynecologic, Ovarian
Drug Dasatinib
